ABBOTT ROLLING OUT LCx CHLAMYDIA TEST IN U.S. FOLLOWING 510(K) CLEARANCE; CORPORATE SALES HIT $10 BIL. IN 1995, UP 9.6%; HOSPITAL/LAB SALES GAIN 4.6%
This article was originally published in The Gray Sheet
Abbott Laboratories is launching its LCx gene amplification test for chlamydia following receipt of 510(k) clearance from FDA on Dec. 8. The urine-based test is the first semi-automated gene amplification test to reach the U.S. market.
You may also be interested in...
Pfizer has now received a formal European Commission approval for its Nyvepria biosimilar pegfilgrastim. The approval puts the firm in direct competition with several other versions of the Neulasta original.
AstraZeneca's research head admits that the half dose approach was a lucky mistake - but one that could boost the vaccine's effectiveness and supplies. The US regulator may not be persuaded, however.
Alvotech has struck a major deal with Yangtze River Pharmaceutical that will allow eight of the biosimilars developer’s products to be commercialized in China.